No there isn't a current suggestion the trial may
Post# of 72440
I cannot even remember where I heard the increase from 3 to 5 days of dosing came from, but then I talk with a lot of people and hear a lot of varying ideas.
But I did hear it somewhere and if that is indeed the case, then my question is relevant.
If the extension is not the case, then my question becomes moot.
I believe the question is relevant as why wouldn't a trial between a new drug and the SOC be on the same footing (as in days of dosing) to get apples to apples data?
If we don't get any word on this subject it will not cause me to lose any sleep. If we do get word, I think it will be an OK to extend the dosing as I am sure they are not finding any safety issues with Brilacidin in the trial.